Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 35Carcinoma, Neuroendocrine 10Carcinoid Tumor 10Neoplasms 6Adenoma, Islet Cell 6Carcinoma, Renal Cell 5Carcinoma, Islet Cell 5Somatostatinoma 4Pheochromocytoma 4Insulinoma 4Glucagonoma 4Carcinoma, Medullary 4Paraganglioma 3Neoplasm Metastasis 3Gastrinoma 3Carcinoma 3Thyroid Neoplasms 2Thyroid Carcinoma, Anaplastic 2Thyroid Cancer, Papillary 2Neuroectodermal Tumors, Primitive 2Liver Neoplasms 2Head and Neck Neoplasms 2Gastro-enteropancreatic neuroendocrine tumor 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Merkel Cell 2Carcinoma, Hepatocellular 2Adenocarcinoma, Follicular 2von Hippel-Lindau Disease 1Zollinger-Ellison Syndrome 1Tuberous Sclerosis 1

Interventions

Paclitaxel 1Everolimus 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Large Cell × Everolimus × Endocrine × Clear all
NCT01317615 2016-03-30

RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation

Novartis

Phase 4 Completed
49 enrolled 11 charts
EndocrineNETThoracic

Lung Neoplasms, Carcinoma, Large Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡